Phase II trial of carboplatin and infusional cyclosporine in platinum-resistant recurrent ovarian

Cancer Chemotherapy and Pharmacology

Volumn 54, Issue 4, 2004, Pages 283-289

  Morgan Jr , Robert J ^a   Synold, Timothy W ^a   Gandara, David ^c   Muggia, Franco ^b   Scudder, Sidney ^e   Reed, Eddie ^d   Margolin, Kim ^a   Raschko, James ^a   Leong, Lucille ^a   Shibata, Stephen ^a   Tetef, Merry ^a   Vasilev, Steven ^a   McGonigle, Kathryn ^a   Longmate, Jeff ^a   Yen, Yun ^a   Chow, Warren ^a   Somlo, George ^a   Carroll, Mary ^a   Doroshow, James H ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e City of Hope ^*

Author keywords

Chemomodulation; Chemotherapy; Phase II

Indexed keywords

CARBOPLATIN; CYCLOSPORIN A; PLATINUM;

ADULT; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; CELL CULTURE; CLINICAL ARTICLE; CLINICAL TRIAL; CLONOGENIC ASSAY; CONCENTRATION RESPONSE; CONSTIPATION; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG EXPOSURE; DRUG POTENTIATION; DRUG RESISTANCE; FEMALE; GASTROINTESTINAL TOXICITY; GRANULOCYTOPENIA; HEADACHE; HUMAN; HUMAN CELL; HYPERTENSION; IN VITRO STUDY; LIVER TOXICITY; MALE; NAUSEA; OVARY CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CYCLOSPORINE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY;

EID: 4644240023     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-004-0818-x     Document Type: Article

References (27)

1. Atkinson K (1987) Cyclosporin in bone marrow transplantation. Bone Marrow Transplant 1:265-270
2. te Boekhorst PAW, van Kapel J, Schoester M, Sonneveld P (1992) Reversal of typical multidrug resistance by cyclosporin and its non-immunosuppressive analogue SDZ PSC 833 in Chinese hamster ovary cells expressing the mdr1 phenotype. Cancer Chemother Pharmacol 30:238-242
3. Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748-1756
4. Cantz T, Nies AT, Brom M, Hofmann AF, Keppler D (2000) MRP2, a human conjugate export pump, is present and transports fluo 3 into apical vacuoles of Hep G2 cells. Am J Physiol Gastrointest Liver Physiol 278:G522-G531
5. Chambers SK, Davis CA, Chambers JT, Schwartz PE, Lorber MI, Hschumacher RE (1996) Phase I trial of intravenous carboplatin and cyclosporin A in refractory gynecologic cancer patients. Clin Cancer Res 2:1699-1704
6. Chambers SK, Davis CA, Schwartz PE, Kohorn EI, Chambers JT (1996) Modulation of platinum sensitivity and resistance by cyclosporin A in refractory ovarian and Fallopian tube cancer patients: a phase II study. Clin Cancer Res 2:1693-1697
7. Chambers SK, Chambers JT, Davis CA, Kohorn EI, Schwartz PE, Lorber MI, Handschumacher RE, Pizzorno G (1997) Pharmacokinetic and phase I trial of intraperitoneal carboplatin and cyclosporine in refractory ovarian cancer patients. J Clin Oncol 15:1945-1952
8. Chen ZS, Kawabe T, Ono M, Aoki S, Sumizawa T, Furukawa T, Uchiumi T, Wada M, Kuwano M, Akiyama SI (1999). Effect of multidrug resistance-reversing agents on transporting activity of human canalicular multispecific organic anion transporter. Mol Pharmacol 56:1219-1228
9. D'Argenio DZ, Shumitzky A (1979) A program package for simulation and parameter estimation in pharmacokinetic systems. Comput Prog Biomed 9:115-134
10. Gottesman MM, Fojo T, Bates SE (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev 2:48-58
11. Green S, Weiss G (1992) Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 10:239-253
12. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481
13. Kashani-Sabet M, Wang W, Scanlon KJ (1980) Cyclosporine A suppresses cisplatin-induced c-fos gene expression in ovarian carcinoma cells. J Biol Chem 265:11285-11288
14. Lensmeyer GL, Wiebe DA, Carlson IH (1987) Identification and analysis of nine metabolites of cyclosporine in whole blood by liquid chromatography. 1. Purification of analytical standards and optimization of the assay. Clin Chem 33:1841-1850
15. Li Q, Tsang B, Bostick-Bruton F, Reed E (1999) Modulation of excision repair cross complementation group 1 (ERCC-1) mRNA expression by pharmacological agents in human ovarian carcinoma cells. Biochem Pharmacol 57:347-353
16. Lum BL, Kaubisch S, Yahanda AM, Adler KM, Jew L, Ehsan MN, Brophy NA, Halsey J, Gosland MP, Sikic BI (1992) Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. J Clin Oncol 10:1635-1642
17. Manetta A, Boyle J, Berman ML, DiSaia PJ, Lentz S, Liao SY, Mutch D, Slater L (1994) Cyclosporin enhancement of cisplatin chemotherapy in patients with refractory gynecologic cancer. Cancer 73:196-199
18. Morgan RJ Jr, Margolin K, Raschko J, Akman S, Leong L, Somlo G, Scanlon KJ, Ahn C, Carroll M, Doroshow JH (1995) Phase I trial of carboplatin and infusional cyclosporine in advanced malignancy. J Clin Oncol 13:2238-2246
19. Paietta E, Racevskis J, Heavey C, Lichtenstein A, Thomas D, Wiernik PH (1993) Modulation of multidrug resistance in de novo adult acute myeloid leukemia: variable efficacy of reverting agents in vitro. Proc Am Soc Clin Oncol 12:302
20. Scanlon KJ, Wang W, Han H (1990) Cyclosporin A suppresses cisplatin-induced oncogene expression in human cancer cells. Cancer Treat Rev 17 [Suppl A]:27-35
21. Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10
22. Sonneveld P, Durie BGM, Lokhorst HM, Marie JP, Solbu G, Suciu S, Zittoun R, Lowenberg B, Nooter K (1992) Modulation of multidrug-resistant multiple myeloma by cyclosporin. Lancet 340:255-259
23. Twentyman PR (1988) Modification of cytotoxic drug resistance by non-immunosuppressive cyclosporines. Br J Cancer 57:254-258
24. Twentyman PR (1992) Cyclosporins as drug resistance modifiers. Biochem Pharmacol 43:109-117
25. Vogt W, Welsch I (1988) Modified TDx assay for cyclosporine and metabolites for use with whole blood samples. Clin Chem 34:1459-1461
26. Yahanda AM, Adler KM, Fisher GA, Brophy NA, Halsey J, Hardy RI, Gosland MP, Lum BL, Sikic BI (1992) Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance. J Clin Oncol 10:1624-1634
27. Yatscoff RW, Copeland KR, Faraci CJ (1990) Abbott TDx monoclonal antibody assay evaluated for measuring cyclosporine in whole blood. Clin Chem 36:1969-1973